These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86. Enhanced Properties of a Benzimidazole Benzylpyrazole Lysine Demethylase Inhibitor: Mechanism-of-Action, Binding Site Analysis, and Activity in Cellular Models of Prostate Cancer. Carter DM; Specker E; Małecki PH; Przygodda J; Dudaniec K; Weiss MS; Heinemann U; Nazaré M; Gohlke U J Med Chem; 2021 Oct; 64(19):14266-14282. PubMed ID: 34555281 [TBL] [Abstract][Full Text] [Related]
87. Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and 1-Dichloromethylinden-1-ol Analogues. Guillade L; Sarno F; Tarhonskaya H; Nebbioso A; Alvarez S; Kawamura A; Schofield CJ; Altucci L; de Lera ÁR ChemMedChem; 2018 Sep; 13(18):1949-1956. PubMed ID: 30047603 [TBL] [Abstract][Full Text] [Related]
88. KDM4C-mediated senescence defense is a targetable vulnerability in gastric cancer harboring TP53 mutations. Wang K; Gong Z; Chen Y; Zhang M; Wang S; Yao S; Liu Z; Huang Z; Fei B Clin Epigenetics; 2023 Oct; 15(1):163. PubMed ID: 37848946 [TBL] [Abstract][Full Text] [Related]
89. KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. Varghese B; Del Gaudio N; Cobellis G; Altucci L; Nebbioso A Front Oncol; 2021; 11():750315. PubMed ID: 34778065 [TBL] [Abstract][Full Text] [Related]
90. Transcriptomic and Drug Discovery Analyses Reveal Natural Compounds Targeting the KDM4 Subfamily as Promising Adjuvant Treatments in Cancer. Del Moral-Morales A; Salgado-Albarrán M; Ortiz-Gutiérrez E; Pérez-Hernández G; Soto-Reyes E Front Genet; 2022; 13():860924. PubMed ID: 35480330 [TBL] [Abstract][Full Text] [Related]
91. FASNating targets of metformin in breast cancer stem-like cells. Wellberg EA; Anderson SM Horm Cancer; 2014 Dec; 5(6):358-62. PubMed ID: 25172609 [No Abstract] [Full Text] [Related]
92. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia. Boila LD; Chatterjee SS; Banerjee D; Sengupta A Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428 [TBL] [Abstract][Full Text] [Related]
93. Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer. Timme S; Sillem M; Bronsert P; Bogatyreva L; Hauschke D; Zur Hausen A; Werner M; Stickeler E Breast Care (Basel); 2017 Sep; 12(4):244-250. PubMed ID: 29070988 [TBL] [Abstract][Full Text] [Related]
94. Identification of the histone lysine demethylase KDM4A/JMJD2A as a novel epigenetic target in M1 macrophage polarization induced by oxidized LDL. Wang X; Wang S; Yao G; Yu D; Chen K; Tong Q; Ye L; Wu C; Sun Y; Li H; Hermann DM; Doeppner TR; Jin F; Dai Y; Wu J Oncotarget; 2017 Dec; 8(70):114442-114456. PubMed ID: 29383092 [TBL] [Abstract][Full Text] [Related]
95. Calcitonin gene-related peptide exerts anti-inflammatory property through regulating murine macrophages polarization in vitro. Duan JX; Zhou Y; Zhou AY; Guan XX; Liu T; Yang HH; Xie H; Chen P Mol Immunol; 2017 Nov; 91():105-113. PubMed ID: 28892747 [TBL] [Abstract][Full Text] [Related]
96. KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma. Isohookana J; Haapasaari KM; Soini Y; Karihtala P Anticancer Res; 2018 Apr; 38(4):2295-2302. PubMed ID: 29599352 [TBL] [Abstract][Full Text] [Related]
97. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. Jeong SH; Kim HB; Kim MC; Lee JM; Lee JH; Kim JH; Kim JW; Park WY; Kim SY; Kim JB; Kim H; Kim JM; Choi HS; Lim DS J Clin Invest; 2018 Mar; 128(3):1010-1025. PubMed ID: 29400692 [TBL] [Abstract][Full Text] [Related]
98. Membrane-permeable Rab27A is a regulator of the acrosome reaction: Role of geranylgeranylation and guanine nucleotides. Bustos MA; Lucchesi O; Ruete MC; Tomes CN Cell Signal; 2018 Apr; 44():72-81. PubMed ID: 29337043 [TBL] [Abstract][Full Text] [Related]
99. Matrine inhibiting pancreatic cells epithelial-mesenchymal transition and invasion through ROS/NF-κB/MMPs pathway. Huang M; Xin W Life Sci; 2018 Jan; 192():55-61. PubMed ID: 29155301 [TBL] [Abstract][Full Text] [Related]
100. Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy. De Francesco EM; Maggiolini M; Tanowitz HB; Sotgia F; Lisanti MP Oncotarget; 2017 Aug; 8(34):56126-56142. PubMed ID: 28915578 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]